Sparfloxacin - positive economic impact predicted Lori Bonertz Newsletter Article 16 February 2013 Pages: 3 - 3
Biomedical innovation - the key to successful healthcare reform Newsletter Article 16 February 2013 Pages: 4 - 4
Antibacterial monotherapy favourable to the clinical budget holder Newsletter Article 16 February 2013 Pages: 5 - 5
Saliva or blood sampling for drug monitoring in children? Newsletter Article 16 February 2013 Pages: 6 - 6
H. pylori therapy cost effective with and without prior testing Newsletter Article 16 February 2013 Pages: 8 - 8
Antibacterial costs exceed the benefits of treating sore throat Newsletter Article 16 February 2013 Pages: 8 - 8
Nicotine nasal spray is cost effective and possibly cost saving Newsletter Article 16 February 2013 Pages: 9 - 9
Prevalence and cost associated with atopic dermatitis Newsletter Article 16 February 2013 Pages: 10 - 10
PTCA less costly than CABG in coronary artery disease Newsletter Article 16 February 2013 Pages: 10 - 10
Most patients ‘ineligible’ for early stroke treatment Newsletter Article 16 February 2013 Pages: 12 - 12
Greatest improvement in QOL with lowest dose breast cancer therapy Newsletter Article 16 February 2013 Pages: 12 - 12
Intensive insulin improves QOL, but not metabolic control Newsletter Article 16 February 2013 Pages: 12 - 12
Looking at a symptom-based outcome measure for asthma Newsletter Article 16 February 2013 Pages: 13 - 14
Generic portion of managed care market to increase Newsletter Article 16 February 2013 Pages: 15 - 15